Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Huober J, Zhang H, Restuccia E, Lambertini C, Gochitashvili N, Henschel V, Eiger D, Graupner V, Zhukova L, Pedrini J, Huggins-Puhalla S, Chang Y, Jarząb M, Niikura N, Barrios C, IMpassion050 Trial Investigators. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022; 40:2946-2956.
Jun 28, 2022Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jun 28, 2022J Clin Oncol 2022; 40:2946-2956
Huober Jens, Zhang Hong, Restuccia Eleonora, Lambertini Chiara, Gochitashvili Nino, Henschel Volkmar, Eiger Daniel, Graupner Vilma, Zhukova Lyudmila, Pedrini José, Huggins-Puhalla Shannon L, Chang Yuan-Ching, Jarząb Michał, Niikura Naoki, Barrios Carlos H, IMpassion050 Trial Investigators
Peripheral neuropathy following COVID-19 mRNA vaccination – 2 Case Reports
Dorin P, Leupold D, Felbecker A, Hundsberger T (2022). Peripheral neuropathy following COVID-19 mRNA vaccination – 2 Case Reports.
Jun 25, 2022Peripheral neuropathy following COVID-19 mRNA vaccination – 2 Case Reports
Jun 25, 20228th EAN Congress
Dorin Patrick, Leupold Daniela, Felbecker Ansgar, Hundsberger Thomas
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC cancer 2022; 22:672.
Jun 18, 2022Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
Jun 18, 2022BMC cancer 2022; 22:672
van Heek Lutz, Stuka Colin, Kaul Helen, Müller Horst, Mettler Jasmin, Hitz Felicitas, Baues Christian, Fuchs Michael, Borchmann Peter, Engert Andreas, Dietlein Markus, Voltin Conrad-Amadeus, Kobe Carsten
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer H, Sperb R, Stussi G, Winkler A, Zenhäusern R, Goede J. Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q). Hemasphere 2022; 6:e741.
Jun 17, 2022Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Jun 17, 2022Hemasphere 2022; 6:e741
Rüfer Axel, Angermann Hubert, Benz Rudolf, Bonadies Nicolas, Calderoni Antonello, Cantoni Nathan, Efthymiou Anna, Escher Robert, Favre Geneviève, Friess Dorothea, Gschwend Andreas, Himmelmann Andreas, Holbro Andreas, Keller Peter, Kouroupi Eirini, Lehmann Thomas, Pedarnig Nikolaus, Rigamonti Véronique, Samii Kaveh, Schmidt Adrian, Schäfer Hans-Peter, Sperb Roland, Stussi Georg, Winkler Annette, Zenhäusern Reinhard, Goede Jeroen
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. Swiss Med Wkly 2022; 152:w30175.
Jun 16, 2022Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Jun 16, 2022Swiss Med Wkly 2022; 152:w30175
Aeppli Stefanie, Engeler Daniel, Fischer Stefanie, Omlin Aurelius, Pratsinis Manolis, Hermann Christian, Rothermundt Christian
Grenzerfahrung Gott
Renz M. Grenzerfahrung Gott - Dem Geheimnis nahe in Leid und Krankheit. Basel: Herder, 2022. ISBN 978-3-451-03322-3.
Jun 13, 2022Grenzerfahrung Gott
Jun 13, 2022Herder, ISBN 978-3-451-03322-3
Renz Monika
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Dafni U, Soo R, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J, de Castro J, Coate L, Früh M, Hashemi S, Nadal E, Carcereny E, Sala M, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open 2022; 7:100507.
Jun 10, 2022Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
Jun 10, 2022ESMO Open 2022; 7:100507
Dafni U, Soo R A, Peters S, Tsourti Zoi, Zygoura P, Vervita K, Han J-Y, de Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio Pulla M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A
A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany
Baaken D, Schmidberger H, Blettner M, Wiegel T, Bartkowiak D, Renner J, Ghilescu V, Merz T, Mose S, Mayr M, Wöckel A, Janni W, Schwentner L, Bekes I, Schmidt M, Merzenich H, Wollschläger D. A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany. Breast 2022; 65:1-7.
Jun 9, 2022A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany
Jun 9, 2022Breast 2022; 65:1-7
Baaken Dan, Schmidberger Heinz, Blettner Maria, Wiegel Thomas, Bartkowiak Detlef, Renner Jona, Ghilescu Voica, Merz Thomas, Mose Stephan, Mayr Manfred, Wöckel Achim, Janni Wolfgang, Schwentner Lukas, Bekes Inga, Schmidt Marcus, Merzenich Hiltrud, Wollschläger Daniel
iRECIST and atypical patterns of response to immuno-oncology drugs.
Ramon-Patino J, Schmid S, Lau S, Seymour L, Gaudreau P, Li J, Bradbury P, Calvo E. iRECIST and atypical patterns of response to immuno-oncology drugs. J Immunother Cancer 2022; 10
Jun 1, 2022iRECIST and atypical patterns of response to immuno-oncology drugs.
Jun 1, 2022J Immunother Cancer 2022; 10
Ramon-Patino Jorge Luis, Schmid Sabine, Lau Sally, Seymour Lesley, Gaudreau Pierre-Olivier, Li Janice Juan Ning, Bradbury Penelope Ann, Calvo Emiliano
Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation.
Oliveri F, Basler M, Rao T, Fehling H, Groettrup M. Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation. Front Immunol 2022; 13:870720.
May 30, 2022Immunoproteasome Inhibition Reduces the T Helper 2 Response in Mouse Models of Allergic Airway Inflammation.
May 30, 2022Front Immunol 2022; 13:870720
Oliveri Franziska, Basler Michael, Rao Tata Nageswara, Fehling Hans Joerg, Groettrup Marcus
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol 2022; 12:899272.
May 26, 2022Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
May 26, 2022Front Oncol 2022; 12:899272
Schwestermann Jonas, Besse Andrej, Driessen Christoph, Besse Lenka
Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
Schmitt A, Walter M, Herbrand A, Jörger M, Moffa G, Novak U, Hemkens L, Kasenda B. Characteristics and survival of patients with cancer with intended off-label use-a cohort study. BMJ Open 2022; 12:e060453.
May 24, 2022Characteristics and survival of patients with cancer with intended off-label use-a cohort study.
May 24, 2022BMJ Open 2022; 12:e060453
Schmitt Andreas Michael, Walter Martin A, Herbrand Amanda Katherina, Jörger Markus, Moffa Giusi, Novak Urban, Hemkens Lars G, Kasenda Benjamin
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
Chumsri S, Holmes E, Di Cosimo S, Werner O, Huober J, Dueck A, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson K, Perez E, Van Dooren V, Hilbers F, Carey L, Li Z, Serie D, Norton N, Mashadi-Hossein A, Tenner K, Brauer H, Warren S, Danaher P, Colon-Otero G, Partridge A, Thompson E. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer 2022; 8:68.
May 24, 2022Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials
May 24, 2022NPJ Breast Cancer 2022; 8:68
Chumsri Saranya, Holmes Eileen, Di Cosimo Serena, Werner Olena, Huober Jens, Dueck Amylou C, Sotiriou Christos, Saura Cristina, Moreno-Aspitia Alvaro, Knutson Keith L, Perez Edith A, Van Dooren Veerle, Hilbers Florentine, Carey Lisa A, Li Zhuo, Serie Daniel J, Norton Nadine, Mashadi-Hossein Afshin, Tenner Kathleen, Brauer Heather Ann, Warren Sarah, Danaher Patrick, Colon-Otero Gerardo, Partridge Ann H, Thompson E Aubrey
Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
Lalive d'Epinay M, Güsewell S, Graf N, Mey U, Driessen C, Hitz F. Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting. Hematol Oncol 2022; 40:716-723.
May 22, 2022Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
May 22, 2022Hematol Oncol 2022; 40:716-723
Lalive d'Epinay Murielle, Güsewell Sabine, Graf Nicole, Mey Ulrich J M, Driessen Christoph, Hitz Felicitas
Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
Begré U, Jörger M, Aebi S, Amstutz U, Largiadèr C. Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. Front Pharmacol 2022; 13:885259.
May 18, 2022Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland.
May 18, 2022Front Pharmacol 2022; 13:885259
Begré Ursina B M, Jörger Markus, Aebi Stefan, Amstutz Ursula, Largiadèr Carlo R
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. Ann Oncol 2022; 33:743-744.
May 18, 2022Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]
May 18, 2022Ann Oncol 2022; 33:743-744
Loibl S, Schmitt W D, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P A, Weber K, Rhiem K, Denkert C, Jackisch C, Rezai M, Engels K, Untch M, Burchardi N, Huober Jens, Sinn B V, Blohmer J-U, Grischke E-M, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos M, Richardson P, Bahlis N, Grosicki S, Cavo M, Beksac M, Legieć W, Liberati A, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach J, Petrucci M, Reece D, White D, Mateos M, Špička I, Lazaroiu M, Berdeja J, Kaufman J, Jou Y, Ganetsky A, Popa McKiver M, Lonial S, Weisel K, Driessen C. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2022; 9:e403-e414.
May 9, 2022Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
May 9, 2022Lancet Haematol 2022; 9:e403-e414
Dimopoulos Meletios A, Richardson Paul G, Bahlis Nizar, Grosicki Sebastian, Cavo Michele, Beksac Meral, Legieć Wojciech, Liberati Anna Marina, Goldschmidt Hartmut, Belch Andrew, Magen Hila, Larocca Alessandra, Laubach Jacob, Petrucci Maria Teresa, Reece Donna, White Darrell, Mateos Maria-Victoria, Špička Ivan, Lazaroiu Mihaela, Berdeja Jesus G, Kaufman Jonathan L, Jou Ying-Ming, Ganetsky Alex, Popa McKiver Mihaela, Lonial Sagar, Weisel Katja, Driessen Christoph
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.
Ditsch N, Wöckel A, Untch M, Jackisch C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Kreipe H, Krug D, Kühn T, Kümmel S, Kolberg-Liedtke C, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Witzel I, Müller V, Janni W, Thill M. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17:403-420.
May 5, 2022AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.
May 5, 2022Breast Care (Basel) 2022; 17:403-420
Ditsch Nina, Wöckel Achim, Untch Michael, Jackisch Christian, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja N, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Heil Jörg, Huober Jens, Kreipe Hans H, Krug David, Kühn Thorsten, Kümmel Sherko, Kolberg-Liedtke Cornelia, Loibl Sibylle, Luftner Diana, Lux Michael Patrick, Maass Nicolai, Mundhenke Christoph, Nitz Ulrike, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Witzel Isabell, Müller Volkmar, Janni Wolfgang, Thill Marc
Postoperative radiotherapy for meningiomas - a decision-making analysis.
Fischer G, Brügge D, Andratschke N, Baumert B, Bosetti D, Caparrotti F, Herrmann E, Papachristofilou A, Rogers S, Schwyzer L, Zwahlen D, Hundsberger T, Putora P. Postoperative radiotherapy for meningiomas - a decision-making analysis. BMC cancer 2022; 22:492.
May 4, 2022Postoperative radiotherapy for meningiomas - a decision-making analysis.
May 4, 2022BMC cancer 2022; 22:492
Fischer Galina Farina, Brügge Detlef, Andratschke Nicolaus, Baumert Brigitta Gertrud, Bosetti Davide Giovanni, Caparrotti Francesca, Herrmann Evelyn, Papachristofilou Alexandros, Rogers Susanne, Schwyzer Lucia, Zwahlen Daniel Rudolf, Hundsberger Thomas, Putora Paul Martin
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.
Thill M, Luftner D, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17:421-429.
May 2, 2022AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.
May 2, 2022Breast Care (Basel) 2022; 17:421-429
Thill Marc, Luftner Diana, Kolberg-Liedtke Cornelia, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Lux Michael, Maass Nicolai, Mundhenke Christoph, Nitz Ulrike, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Müller Volkmar, Janni Wolfgang, Ditsch Nina